linical results,
uncertainties relating to preclinical and clinical trials; success in the
clinical development of any products; dependence on third parties; future
capital needs; and risks relating to the commercialization, if any, of the
Company's proposed products (such as marketing, safety, regulatory, patent,
product liability, supply, competition and other risks).
CONTACT:
Ginny Dunn
Associate Director,
Corporate Communications & Investor Relations
EntreMed, Inc.
240-864-2643
ENTREMED, INC.
SUMMARY OF OPERATING RESULTS
Three Months Ended
December 31,
2007 2006
Total revenues $3,875,392 $3,871,173
Research and development $5,650,152 $7,857,677
General and administrative $1,978,982 $2,136,764
Net loss $(3,767,496) $(5,627,632)
Dividend on Series A convertible
preferred stock $(251,250) $(251,250)
Net loss attributable to common
shareholders $(4,018,746) $(5,878,882)
Net loss per share attributable to
common shareholders (basic and diluted) $(0.05) $(0.08)
Weighted average number of
shares outstanding (basic and diluted) 84,362,710 74,606,821
Twelve Months Ended
December 31,
2007 2006
Total revenues $7,395,651 $6,894,358
Research and development $23,739,392 $21,671,117
General and administrative $7,386
'/>"/>
SOURCE EntreMed, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference2.
EntreMed Appoints Senior Vice President of Research and Development3.
EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-20764.
EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study5.
EntreMed to Present at BIO CEO and Investor Conference6.
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound7.
QMed, Inc. Reports July Medicare SNP Enrollments8.
Phlo Affiliate Reports Expanded Coverage to Oregon Border9.
Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results10.
Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 200711.
Carrington Reports Second Quarter 2007 Results